InfiCure Bio has been accepted to Business Swedens Catalyst program, which is a program aimed at helping companies scale globally. The focus for InfiCure Bio is the Korean market and Business Sweden will help InfiCure to evaluate the potential of the Korean market and the interest in the NIF mouse. We are very excited about this [...]
About wpadminThis author has not yet filled in any details.
So far wpadmin has created 32 blog entries.
The CEO of InfiCure Bio presented the company at LSX Nordics in Stockholm on August 28th. To watch the presentation click here.
InfiCure Bio will be presenting at the LSX Nordic Congress in Stockholm on August 28th. The company will be presenting during the start up showcase as one of the growth stage private companies.
InfiCure Bio has received additional funding from NLC InfiCure Bio and Partnerinvest Övre Norrland to speed up the validation of additional indications in the NIF mouse. This is a golden opportunity to broaden our customer base and increase the revenue of the company.
InfiCure Bio is pleased to announce that Lena Söderström has been appointed new Chairman of the Board. Lena has longstanding experience from numerous positions in the life science sector and her knowledge, together with her extensive network, is exactly what InfiCure Bio needs right now. We are looking forward to the next step in the [...]
InfiCure Bio will be present at this years EASL in Vienna. Julia will present the NIF mouse and Dan will talk about imaging in livers of NIF mice. If you're at EASL, do not hesitate to contact us to schedule a one-to-one meeting.
InfiCure Bio is happy to announce that the our application for Vinnovas grant "Innovationsprojekt i företag" was funded. In this round of applications, InfiCure Bio was the only company in Västerbotten with an approved application. This grant will aid in a faster market introduction of the NIF mouse as a preclinical model for kidney fibrosis.
Read our new pamphlet on the NIF mouse as a model for studies of liver fibrosis. The NIF mouse can be used both as a model for tests of drugs to treat general liver fibrosis, but also as a model for tests of drugs targeting the late inflammatory and/or fibrotic stages of NASH.
The application to Horizon 2020 SME Instrument Phase II submitted by InfiCure Bio i January 2019 was awarded a seal of excellence. This means that the application passed the score set by EU for grant approval, but the amount of money allocated for the call was not enough.
Julia Nilsson, Research Associate at InfiCure Bio, will be presenting at the Keystone Symposium: "Integrated Pathways of Disease in NASH and NAFLD" in Santa Fee January 20-24 2019. Julia will present new data on the NIF mouse as a model for late inflammatory/fibrotic stage of NASH.